Home » Consulting Services » Business and Data Analysis »

Business and Data Analysis

Business and Data Analysis

PHSL uses its vast industry experience along with analysis techniques and financial modeling to solve your toughest business problems. We analyze your situation from different points of view and identify opportunities or potential problems before they occur. Prior to your investment in a new business process or program, let PHSL model and assess its impact on your financial results.

View our case studies related to business and data analysis:

340B Compliance Review

Accounting Firm Required Pharmacy Expertise

Client Selects Copay Reduction Program

Determining Competitive Market Landscape

Drug Resources Made Available via Manufacturer’s Website

Generic Competition Studied to Determine Effects on Brand Drug

Generic Market Forecasting

Health Systems Seeks Insight on Increasing Biosimilar Adoption Rate

Industry Monitoring, Research, & Analysis Used as a Vital Decision Resource

Manufacturer Seeks Pre-Launch Rebate Level Forecasting

Medicare PDP Develops Community Pharmacy MTM Program

PBM Contract Variance Analysis

PBM Positions Itself for Increased Rebate Yield

PHSI Helps PBM Develop a Pharmacy Network Contracting Strategy

PHSI Helps Supermarket Chain Move Toward Providing Pharmaceutical Care

Proactive Response to Loss of Brand Patent Protection

Rebate Contracting Consolidation Process Directed by PHSI

Research Updates Brand Designation in Drug Databases

Seasonal-Use Product Reimbursement Trend Analysis

Specialty Drug Reimbursement by Pharmacy Type

U&C Pricing Strategy Critical for Chain Expansion

November 2020 Question of the Month

How will hospital and insurance plan price transparency impact patient costs?

Patients won’t notice: 40%

No impact: 20%

Increase patient costs: 20%

Decrease patient costs: 20%

October 2020 Question of the Month

What change do you most expect to see in the 340B program in the next year?

Reduced drug sales at 340B prices: 60%

Legislative changes to 340B program: 20%

HRSA lawsuit challenging 340B sales limitations by manufacturers: 20%

Shifting drug sales to 340B supportive manufacturers: 0%

September 2020 Question of the Month

Many industry conferences have been cancelled or shifted online due to COVID-19. How are you staying connected to industry colleagues?

Scheduling regular calls or online meetings: 54.5%

Participating in virtual conferences: 9.1%

Social media: 9.1%

All of the above: 27.3%

None of the above: 0%